+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Thyroid Cancer Drugs Market Research Report by Drug Type (Cabozantinib-S-Malate, Caprelsa, and Cometriq), End User, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 121 Pages
  • July 2022
  • Region: United States
  • 360iResearch™
  • ID: 5460205
UP TO OFF until Dec 31st 2022
The United States Thyroid Cancer Drugs Market size was estimated at USD 120.32 million in 2021, USD 129.51 million in 2022, and is projected to grow at a CAGR 9.52% to reach USD 207.72 million by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Thyroid Cancer Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Type, the market was studied across Cabozantinib-S-Malate, Caprelsa, Cometriq, Doxorubicin Hydrochloride, Ipilimumab, Lenvatinib Mesylate, Nivolumab, and Vandetanib.
  • Based on End User, the market was studied across Hospitals, Oncology Clinics, and Research Organizations.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Thyroid Cancer Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Thyroid Cancer Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Thyroid Cancer Drugs Market, including Abbott Laboratories, Alara Pharmaceutical Corporation, App pharmaceuticals LLC, AstraZeneca PLC, Baxter International Inc., Bayer AG, Bio-Path Holdings, Biovista Inc., Bristol Myers co., Cytori Therapeutics, Inc., Eisai Co., Ltd., Eli Lilly and Company, Exelixis Inc., GlaxoSmithKline PLC, Jerome Stevens Pharmaceuticals Inc., Lupin, Merck & Co., Inc, Mylan Pharmaceuticals Inc., Novartis International AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, and Vascular Biogenics Ltd..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States Thyroid Cancer Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Thyroid Cancer Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Thyroid Cancer Drugs Market?
4. What is the competitive strategic window for opportunities in the United States Thyroid Cancer Drugs Market?
5. What are the technology trends and regulatory frameworks in the United States Thyroid Cancer Drugs Market?
6. What is the market share of the leading vendors in the United States Thyroid Cancer Drugs Market?
7. What modes and strategic moves are considered suitable for entering the United States Thyroid Cancer Drugs Market?
Frequently Asked Questions about the U.S. Thyroid Cancer Drugs Market

What is the estimated value of the U.S. Thyroid Cancer Drugs Market?

The U.S. Thyroid Cancer Drugs Market was estimated to be valued at $120.32 Million in 2021.

What is the growth rate of the U.S. Thyroid Cancer Drugs Market?

The growth rate of the U.S. Thyroid Cancer Drugs Market is 9.5%, with an estimated value of $207.72 Million by 2027.

What is the forecasted size of the U.S. Thyroid Cancer Drugs Market?

The U.S. Thyroid Cancer Drugs Market is estimated to be worth $207.72 Million by 2027.

Who are the key companies in the U.S. Thyroid Cancer Drugs Market?

Key companies in the U.S. Thyroid Cancer Drugs Market include Abbott Laboratories, Alara Pharmaceutical Corporation, App pharmaceuticals LLC, AstraZeneca PLC, Baxter International Inc., Bayer AG, Bio, Path Holdings and Bristol Myers co..

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Thyroid Cancer Drugs Market, by Drug Type
6.1. Introduction
6.2. Cabozantinib-S-Malate
6.3. Caprelsa
6.4. Cometriq
6.5. Doxorubicin Hydrochloride
6.6. Ipilimumab
6.7. Lenvatinib Mesylate
6.8. Nivolumab
6.9. Vandetanib
7. Thyroid Cancer Drugs Market, by End-user
7.1. Introduction
7.2. Hospitals
7.3. Oncology Clinics
7.4. Research Organizations
8. California Thyroid Cancer Drugs Market9. Florida Thyroid Cancer Drugs Market10. Illinois Thyroid Cancer Drugs Market11. New York Thyroid Cancer Drugs Market12. Ohio Thyroid Cancer Drugs Market13. Pennsylvania Thyroid Cancer Drugs Market14. Texas Thyroid Cancer Drugs Market
15. Competitive Landscape
15.1. Fpnv Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis
15.3. Market Share Analysis, by Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion
16. Company Usability Profiles
16.1. Abbott Laboratories
16.2. Alara Pharmaceutical Corporation
16.3. App Pharmaceuticals LLC
16.4. Astrazeneca plc
16.5. Baxter International Inc.
16.6. Bayer Ag
16.7. Bio-Path Holdings
16.8. Biovista Inc.
16.9. Bristol Myers Co.
16.10. Cytori Therapeutics, Inc.
16.11. Eisai Co., Ltd.
16.12. Eli Lilly and Company
16.13. Exelixis Inc.
16.14. GlaxoSmithKline plc
16.15. Jerome Stevens Pharmaceuticals Inc.
16.16. Lupin
16.17. Merck & Co., Inc
16.18. Mylan Pharmaceuticals Inc.
16.19. Novartis International Ag
16.20. Pfizer Inc.
16.21. Takeda Pharmaceutical Company Limited
16.22. Teva Pharmaceutical Industries Ltd
16.23. Vascular Biogenics Ltd.
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES THYROID CANCER DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, 2021 VS 2027 (USD MILLION)
FIGURE 3. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 4. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2027
FIGURE 7. UNITED STATES THYROID CANCER DRUGS MARKET DYNAMICS
FIGURE 8. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2027
FIGURE 11. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY CABOZANTINIB-S-MALATE, 2019-2027 (USD MILLION)
FIGURE 12. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY CABOZANTINIB-S-MALATE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 13. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY CAPRELSA, 2019-2027 (USD MILLION)
FIGURE 14. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY CAPRELSA, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 15. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY COMETRIQ, 2019-2027 (USD MILLION)
FIGURE 16. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY COMETRIQ, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 17. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY DOXORUBICIN HYDROCHLORIDE, 2019-2027 (USD MILLION)
FIGURE 18. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY DOXORUBICIN HYDROCHLORIDE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 19. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY IPILIMUMAB, 2019-2027 (USD MILLION)
FIGURE 20. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY IPILIMUMAB, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 21. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY LENVATINIB MESYLATE, 2019-2027 (USD MILLION)
FIGURE 22. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY LENVATINIB MESYLATE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 23. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, 2019-2027 (USD MILLION)
FIGURE 24. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 25. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY VANDETANIB, 2019-2027 (USD MILLION)
FIGURE 26. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY VANDETANIB, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 27. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2021 VS 2027 (%)
FIGURE 28. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2021 VS 2027 (USD MILLION)
FIGURE 29. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2027
FIGURE 30. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2019-2027 (USD MILLION)
FIGURE 31. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 32. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, 2019-2027 (USD MILLION)
FIGURE 33. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 34. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, 2019-2027 (USD MILLION)
FIGURE 35. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 36. CALIFORNIA THYROID CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 37. FLORIDA THYROID CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 38. ILLINOIS THYROID CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 39. NEW YORK THYROID CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 40. OHIO THYROID CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 41. PENNSYLVANIA THYROID CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 42. TEXAS THYROID CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 43. UNITED STATES THYROID CANCER DRUGS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 44. UNITED STATES THYROID CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 45. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES THYROID CANCER DRUGS MARKET, BY TYPE
List of Tables
TABLE 1. UNITED STATES THYROID CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 4. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2019-2027 (USD MILLION)
TABLE 5. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY CABOZANTINIB-S-MALATE, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY CAPRELSA, BY STATE, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY COMETRIQ, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY DOXORUBICIN HYDROCHLORIDE, BY STATE, 2019-2027 (USD MILLION)
TABLE 10. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY IPILIMUMAB, BY STATE, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY LENVATINIB MESYLATE, BY STATE, 2019-2027 (USD MILLION)
TABLE 12. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, BY STATE, 2019-2027 (USD MILLION)
TABLE 13. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY VANDETANIB, BY STATE, 2019-2027 (USD MILLION)
TABLE 14. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 15. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY STATE, 2019-2027 (USD MILLION)
TABLE 16. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY STATE, 2019-2027 (USD MILLION)
TABLE 17. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY STATE, 2019-2027 (USD MILLION)
TABLE 18. CALIFORNIA THYROID CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 19. CALIFORNIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 20. CALIFORNIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 21. FLORIDA THYROID CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 22. FLORIDA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 23. FLORIDA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 24. ILLINOIS THYROID CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 25. ILLINOIS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 26. ILLINOIS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 27. NEW YORK THYROID CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 28. NEW YORK THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 29. NEW YORK THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 30. OHIO THYROID CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 31. OHIO THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 32. OHIO THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 33. PENNSYLVANIA THYROID CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 34. PENNSYLVANIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 35. PENNSYLVANIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 36. TEXAS THYROID CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 37. TEXAS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 38. TEXAS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2019-2027 (USD MILLION)
TABLE 39. UNITED STATES THYROID CANCER DRUGS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 40. UNITED STATES THYROID CANCER DRUGS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 41. UNITED STATES THYROID CANCER DRUGS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 42. UNITED STATES THYROID CANCER DRUGS MARKET RANKING
TABLE 43. UNITED STATES THYROID CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 44. UNITED STATES THYROID CANCER DRUGS MARKET MERGER & ACQUISITION
TABLE 45. UNITED STATES THYROID CANCER DRUGS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 46. UNITED STATES THYROID CANCER DRUGS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 47. UNITED STATES THYROID CANCER DRUGS MARKET INVESTMENT & FUNDING
TABLE 48. UNITED STATES THYROID CANCER DRUGS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 49. UNITED STATES THYROID CANCER DRUGS MARKET: LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • Alara Pharmaceutical Corporation
  • App pharmaceuticals LLC
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Bio-Path Holdings
  • Biovista Inc.
  • Bristol Myers co.
  • Cytori Therapeutics, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis Inc.
  • GlaxoSmithKline PLC
  • Jerome Stevens Pharmaceuticals Inc.
  • Lupin
  • Merck & Co., Inc
  • Mylan Pharmaceuticals Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Vascular Biogenics Ltd.

Methodology

Loading
LOADING...